Jillian Kallman Price, Lynn H Gerber, Maria Stepanova, Leyla de Avila, Ali A Weinstein, Huong Pham, Fatema Nader, Mariam Afendy, Kathy Terra, Patrick Austin, Wisna'odom Keo, Andrei Racila, James Michael Estep, Suzannah Gerber, Manisha Verma, Pegah Golabi, Brian P Lam, Zobair Younossi
INTRODUCTION: Many with post-acute SARS-CoV-2 (PASC) have persistent symptoms impacting physical and cognitive function, decreased health and health-related life quality. Monoclonal antibody (mAb) treatment was available to acutely infected patients which might improve these outcomes. PURPOSE: To compare patient perception of PASC symptoms for those receiving bamlanivimab or casirivimab and imdevimab (mAbs) to those not receiving this treatment (non-mAbs). To compare changes between these groups in symptoms, function and quality of life over a 6-month follow-up...
2023: International Journal of General Medicine